论文部分内容阅读
目的分析探讨妊娠合并子宫肌瘤的患者在剖宫产术中的处理方法,以及剖宫产术同时行子宫肌瘤剔除术的安全性及可行性。方法回顾性分析河北省民政总医院2009年1月—2013年1月剖宫产术中同时行肌瘤剔除术的80例产妇及同期仅行剖宫产而未剔除肌瘤的86例产妇的临床资料,观察2组围术期(手术时间、术中出血量、产后出血率、住院天数、产褥病率等)情况进行全面对比分析。数据采用SPSS 16.0统计软件进行分析,计量资料采用t检验,计数资料采用χ2检验。结果剖宫产术中肌瘤剔除组与不剔除组除手术时间差异有统计学意义(P<0.05)外,2组手术其他围术期(手术时间、术中出血量、产后出血率、住院天数、产褥病率等)情况比较差异无统计学意义(P>0.05)。结论妊娠合并子宫肌瘤的患者在剖宫产术中是否应同时行肌瘤剔除术应因人而异,根据患者的具体情况,由有经验的医师在剖宫产术中同时选择性行子宫肌瘤剔除术并未明显增加手术的风险,是安全可行的,并可降低患者日后的二次手术发生率,值得临床推广应用。
Objective To investigate the treatment of patients with pregnancy complicated with uterine fibroids in cesarean section, as well as cesarean section at the same time the safety and feasibility of myomectomy. Methods A retrospective analysis of Hebei Province Civil Affairs General Hospital from January 2009 to January 2013 cesarean section at the same time myomectomy 80 cases of maternal and same-time only cesarean section without excluding fibroids 86 cases of maternal Clinical data, the two groups were observed during the perioperative period (operation time, intraoperative blood loss, postpartum hemorrhage, hospitalization days, puerperal morbidity, etc.) a comprehensive comparative analysis. Data were analyzed using SPSS 16.0 statistical software, measurement data using t test, count data using χ2 test. Results In the cesarean section, except the operation time, there were significant differences between the two groups (P <0.05). The other perioperative periods (operation time, intraoperative blood loss, postpartum hemorrhage rate, hospitalization Days, puerperal morbidity, etc.) was no significant difference (P> 0.05). Conclusions Patients with pregnancy complicated with uterine fibroids in cesarean section should be simultaneously myomectomy should vary from person to person, according to the specific circumstances of the patient, by experienced physicians in the cesarean section at the same time select the uterus Myomectomy did not significantly increase the risk of surgery is safe and feasible, and can reduce the incidence of secondary surgery in patients with future, it is worth promoting the clinical application.